ArticleBMC complementary medicine and therapies2026
Acute neurotoxicity in a child following multi-component medicinal fungi supplementation: a case report.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medicinal Mushrooms and Their Bioactive Compounds: From Traditional Use to Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedicinal fungi supplements have gained widespread recognition, increasing off-label use in pediatric populations. However, their safety profile remains inadequately characterized, and the potential for toxic effects, including neurotoxicity, is underrecognized in clinical practice. Here we report a pediatric case of suspected multi-component medicinal fungi supplement-related neurotoxicity, in which the parents were aware that the ingredient was a mushroom for their son's alternative treatment. CASE PRESENTATION: We report acute neurotoxicity in a 9-year-old boy with prematurity, cerebral palsy, and well-controlled epilepsy presenting with generalized myoclonic seizures, hallucinations, and altered mental status following ingestion of multiple medicinal fungi supplements, including Ganoderma lucidum and Cordyceps sinensis. Comprehensive investigations, including laboratory studies and neuroimaging, excluded infectious, structural, and metabolic etiologies. The temporal relationship between dose escalation of the supplement and symptom onset, combined with resolution upon discontinuation, suggested a supplement-related mechanism.
conclusionsThis case highlights the potential neurotoxic effects of mushroom supplements containing both Ganoderma lucidum (reishi mushroom) and Cordyceps sinensis in children with underlying neurological disorders. The temporal association between dose escalation and symptom onset, with complete symptom resolution upon discontinuation, suggests a supplement-related mechanism. Given the increasing use of medicinal fungi in complementary medicine, greater clinical vigilance and public awareness of their potential risks are essential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.